Home › Calculator › BEAM Dividend Calculator 2026
BEAM Dividend Calculator 2026
No dividendHealthcareBeam Therapeutics Inc. · NASDAQ
Price: $24.05 · Annual div: None · Frequency: — · Payout ratio: N/A · Ex-div: —
Calculator settings
BEAM is not a dividend-focused stock
BEAM pays a very low or no dividend (Yield: 0.00%). This calculator is designed for income-producing assets. If your goal is passive income and compounding, you might want to look at these popular alternatives:
Portfolio growth: DRIP vs No DRIP
Annual dividend income growth
BEAM Dividend Yield
Beam Therapeutics Inc. (BEAM) does not currently pay a regular dividend in our data, so its dividend yield is 0%.
💡 What-if scenarios
Click to apply scenario to the calculator
🎯 When BEAM pays your bills
Year your monthly dividend income covers each expense (based on current settings)
About Beam Therapeutics Inc. (BEAM) — Dividend Analysis 2026
Beam Therapeutics Inc., founded in 2017 and based in Cambridge, Massachusetts, operates as a pioneering biopharmaceutical firm. Its core mission involves engineering precise genetic remedies to tackle a spectrum of severe human ailments, primarily within the United States. The company's developmental portfolio features several key candidates: BEAM-101 is being advanced to treat both sickle cell disease and beta thalassemia. BEAM-102 is specifically designed for addressing sickle cell disease. BEAM-201, an allogeneic chimeric antigen receptor T-cell therapy, is under investigation for individuals suffering from relapsed or refractory T-cell acute lymphoblastic leukemia. BEAM-301 is a liver-targeted candidate aimed at patients afflicted with Glycogen Storage Disease Type Ia. Beyond these flagship programs, Beam Therapeutics is also engaged in devising treatments for alpha-1 antitrypsin deficiency, various ocular conditions, and other disorders impacting the liver, muscular system, and central nervous system. To further its research and development objectives, Beam Therapeutics has forged numerous strategic alliances and partnerships. These include collaborations with Boston Children's Hospital; a research and clinical trial agreement with Magenta Therapeutics, Inc.; a licensing deal with Sana Biotechnology, Inc.; and a research partnership with the Institute of Molecular and Clinical Ophthalmology Basel. Additionally, the company maintains research collaborations with both Pfizer Inc. and Apellis Pharmaceuticals, Inc., alongside a comprehensive collaboration and license agreement with Verve Therapeutics, Inc.
BEAM Dividend & DRIP — Frequently Asked Questions
Does BEAM pay a dividend?
No. Beam Therapeutics Inc. (BEAM) has not paid a regular dividend in the last 12 months in our data, so its dividend yield is 0% and it produces no dividend income.
How can I get dividend income instead of BEAM?
Dividend ETFs such as SCHD, VYM or JEPI pay regular income. Open their DRIP calculators to see what $10,000 would earn per month and how reinvesting grows it.
Does BEAM have a DRIP (dividend reinvestment plan)?
A DRIP reinvests dividends into new shares. BEAM has no regular dividend in our data, so there is nothing to reinvest.
Stocks similar to BEAM
Forward dividend yield from the latest data · open any DRIP calculator
This calculation uses the DividendFlow Engine v6.0. Data is verified daily against SEC filings and FMP real-time feeds to ensure projection accuracy.
Get Your Full BEAM DRIP Report by Email
We'll send you a full breakdown of your projections, DRIP tips, and how to enable dividend reinvestment with your broker.
Free forever. No spam. Unsubscribe anytime. · Privacy Policy
Ready to invest? Open BEAM position with:
🌍 BEAM Yield by Country & Account Type
Real after-tax yield depends on where you live and how you hold BEAM.
| Account/Country | Tax Rate | After-tax Yield | Real Yield | $10K Annual Income |
|---|---|---|---|---|
| 🇺🇸 Roth IRA / 401k | 0% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (15%) ✓ | 15% | 0.00% | -2.80% | $0 / yr |
| 🇺🇸 US Taxable (20%) | 20% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK ISA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇬🇧 UK Taxable | 8.75% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 TFSA | 0% | 0.00% | -2.80% | $0 / yr |
| 🇨🇦 CA Taxable | 25% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 Super (pension) | 15% | 0.00% | -2.80% | $0 / yr |
| 🇦🇺 AU Taxable | 30% | 0.00% | -2.80% | $0 / yr |
| 🇩🇪 DE Taxable | 26.375% | 0.00% | -2.80% | $0 / yr |
| 🇫🇷 FR Taxable | 30% | 0.00% | -2.80% | $0 / yr |
Real yield = after-tax yield minus US CPI of 2.8%. 12-month CPI (US BLS via FMP economic-indicators). Click any row to select. US withholding tax (30%, reducible by treaty) applies to non-US residents holding US stocks in taxable accounts.
🎯 BEAM Income Goal & Break-Even
12-month CPI (US BLS via FMP economic-indicators).
No dividend data available for this ticker.
Based on current dividend of $0.00/share/yr · 🇺🇸 US Taxable (15%) · static projection (no growth assumed).
📅 BEAM Dividend Payment Schedule
BEAM pays quarterly — 4 times per year. Ex-div: —.
📊 BEAM vs Healthcare Benchmarks
How BEAM compares to typical Healthcare averages.
Benchmarks: S&P 500 sector averages (2024–2026). Sources: Morningstar, Bloomberg, NAREIT. 5Y CAGR for BEAM sourced from FMP /financial-growth endpoint — real data, not estimates.
🏛️ BEAM Insider Activity
When executives buy their own stock, it's a signal they believe in the dividend's sustainability.
| Insider | Title | Type | Date | Shares | Price | Total Value |
|---|---|---|---|---|---|---|
| M-Exempt | 2026-10-16 | 25,000 | $1.03 | $25.8K | ||
| Sale | 2026-10-15 | 25,000 | $23.57 | $589.1K | ||
| Sale | 2026-10-16 | 25,000 | $23.98 | $599.6K | ||
| M-Exempt | 2026-10-15 | 25,000 | $1.03 | $25.8K | ||
| M-Exempt | 2026-10-16 | 25,000 | $1.03 | $25.8K | ||
| Sale | 2026-10-01 | 187 | $24.41 | $4.6K | ||
| G-Gift | 2026-09-24 | 123,407 | — | — | ||
| Sale | 2026-07-27 | 16,667 | $25.74 | $429.0K | ||
| Sale | 2026-06-30 | 373 | $34.73 | $13.0K | ||
| M-Exempt | 2026-06-30 | 25,000 | $1.03 | $25.8K |
Insider transactions sourced from SEC Form 4 filings via Financial Modeling Prep. See disclaimer.
Analyst Price Target
Wall Street consensusAnalyst consensus price target via FMP. Not a guarantee of future performance. Past analyst accuracy varies.
Peer Group
Similar companies in the same sectorCompare BEAM with peers: BEAM vs AGIO · BEAM vs COGT · BEAM vs DNLI
Financial Health Scores
Altman Z-Score predicts bankruptcy risk. Piotroski F-Score measures financial strength across 9 criteria. High scores → lower dividend cut risk. Data via FMP financial statements.
Dividend yields, payout ratios, and financial metrics are sourced from Financial Modeling Prep (FMP) and cross-referenced with SEC EDGAR filings. Data is cached and updated every 24 hours via our nightly refresh. DRIP projections are forward-looking estimates, not guarantees.
Educational purposes only. Not financial advice. DividendFlow is not a registered investment advisor. Projections generated by the BEAM dividend calculator are estimates based on historical data and user inputs. Actual future returns, stock prices, and dividend payments will vary. Dividends can be cut or suspended at any time. All investments carry risk, including the loss of principal. Please consult a qualified financial professional before making any investment decisions. Full disclaimer →
Beam Therapeutics Inc. (BEAM) is currently trading at $24.05, 37% below its 52-week high. It does not currently pay a regular dividend.
Does BEAM Pay a Dividend? Beam Therapeutics Inc. Dividend Status
Beam Therapeutics Inc. (BEAM) is a healthcare stock trading at $24.05. It does not currently pay a regular dividend in our data, so it produces no dividend income and DRIP reinvestment does not apply. Investors seeking income often look at dividend ETFs such as SCHD, VYM or JEPI instead.
- Without a dividend, returns depend entirely on the share price.
Auto-generated from live market data. For educational purposes only — not financial advice.
Latest BEAM News
LiveNews aggregated from public sources via Finnhub & RSS. For informational purposes only.
Projected your BEAM DRIP returns?
If DividendFlow helped you see your future dividend income clearly, other investors deserve the same clarity. Your review takes 30 seconds and makes a real difference.